NuCana (NASDAQ:NCNA) Releases Earnings Results, Beats Estimates By $2.11 EPS

NuCana (NASDAQ:NCNA) released its quarterly earnings data on Thursday. The company reported ($0.32) EPS for the quarter, topping analysts’ consensus estimates of ($2.43) by $2.11, Zacks reports.

NuCana Price Performance

NuCana stock opened at $0.79 on Friday. The stock’s 50-day moving average is $0.97 and its 200-day moving average is $1.54. The company has a market cap of $2.09 million, a price-to-earnings ratio of -0.08 and a beta of 0.89. NuCana has a 12 month low of $0.75 and a 12 month high of $10.79.

About NuCana

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells.